

**TEST DOWN**

**NOTIFICATION DATE:** May 21, 2009

**EFFECTIVE DATE:** Immediately

**ALPHA-FETOPROTEIN (AFP) L3% AND TOTAL, HEPATOCELLULAR  
CARCINOMA TUMOR MARKER, SERUM  
#88878**

**EXPLANATION:** Due to instrument technical issues, #88878 Alpha-fetoprotein (AFP) L3% and Total Hepatocellular Carcinoma Tumor Marker assay will be down until further notice. Clients with pending specimens will be contacted and offered referral option Mayo test code #91937 Alpha Fetoprotein, Total & L3 Percent to ARUP Laboratories. Current fees will remain in effect for thirty days.

**RECOMMENDED ALTERNATIVE TEST:** #91937 Alpha Fetoprotein, Total & L3 Percent to ARUP Laboratories.

**METHODOLOGY:** Immunoenzymatic/Liquid Phase Binding

**REFERENCE VALUES:** Alpha Fetoprotein Total: 0-15 ng/mL  
Alpha Fetoprotein L3 %:  $\leq 10.0\%$

**SPECIMEN REQUIREMENTS:**

Draw blood in red-top tube(s) or serum gel tube(s). Separate from cells immediately and submit 1.0 mL serum refrigerate.

**CPT CODE:** 82107

**LIST FEE:** \$175.00

**DAY(S) SET UP:** Thursdays

**ANALYTIC TIME:** 1 day

QUESTIONS: Contact your Mayo Medical Laboratories' Regional Manager  
Greg Renkly Mayo Medical Laboratories' Technical Support  
Telephone: 800-533-1710

## TEST DEFINITION

5/21/2009

Code Name

91937 Alpha Fetoprotein Total+L3 Percent

\*\*\*\* End of Name to order code Report \*\*\*\*

MML MML Test setup information

ORDER CODE	EFF DATE	TC	TITLE	Checking Normals	Print normals (# coded)	Perform Site *
91937	5/21/2009		Alpha Fetoprotein Total+L3 Percent			
			Transport temp : Refrig 1 week\Frozen 3 months\Ambient NO			
		25004	Alpha Fetoprotein Total			
			Units: ng/mL			
			NO SEX			
			All Ages : 0-15		; 0-15	
			MALE			
			All Ages : 0-15		; 0-15	
			FEMALE			
			All Ages : 0-15		; 0-15	
		25005	Alpha Fetoprotein L3%			
			Units: %			
			NO SEX			
			All Ages : 0-10.0		; <=10.0	
			MALE			
			All Ages : 0-10.0		; <=10.0	
			FEMALE			
			All Ages : 0-10.0		; <=10.0	
			TEST CODE ALWAYS MESSAGE - [Z91937]			
		Z91937	TEST INFORMATION: Alpha Fetoprotein L3%			
			The Wako LiBASys method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Wako AFP-L3% assay is intended as a risk assessment test for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated AFP-L3% values have been shown to be associated with a seven-fold increase in the risk of developing hepatocellular			

carcinoma within the next 21 months. Patients with elevated serum AFP-L3% should be more intensely evaluated for evidence of hepatocellular carcinoma. The result is not interpretable as a tumor marker in pregnant females.

Test Performed by: ARUP Laboratories, Inc.  
500 Chipeta Way  
Salt Lake City, UT 84108

-----

MML MML Test setup information

\*Performing Site Legend

=====  
==  
=====  
==

\*\*\* End of Report \*\*\*

MML Messages used as normals

CODE TEXT  
-----

Total of 0 normals codes

\*\*\* End of Report \*\*\*



LABORATORY SERVICE REPORT

1-800-533-1710

PATIENT NAME TESTING, 91937		PATIENT NUMBER		AGE 48	SEX F	ACCESSION # W1356527
ORDERING PHYSICIAN		CLIENT ORDER #				ACCOUNT # LIAISONS
COLLECTION 05/21/09 11:48 A	RECEIVED 05/21/09 11:48 A	REPORT PRINTED 05/21/09 03:10 P		SPECIMEN INFORMATION DATE OF BIRTH: 6/23/1960		
<b>DATE</b>	<b>TIME</b>	<b>DATE</b>	<b>TIME</b>			
Test Client Attn: Mayo Liaisons 200 First Street SW Rochester, MN 55905 507-284-8202						

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *
----------------	----------	-----------	----------------

**Alpha Fetoprotein Total+L3 Percent**

Alpha Fetoprotein Total	10	ng/mL	0-15	REF
Alpha Fetoprotein L3%	<0.5	%	<=10.0	REF

**TEST INFORMATION: Alpha Fetoprotein L3%**

The Wako LiBASys method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The Wako AFP-L3% assay is intended as a risk assessment test for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated AFP-L3% values have been shown to be associated with a seven-fold increase in the risk of developing hepatocellular carcinoma within the next 21 months. Patients with elevated serum AFP-L3% should be more intensely evaluated for evidence of hepatocellular carcinoma. The result is not interpretable as a tumor marker in pregnant females.

Test Performed by: ARUP Laboratories, Inc.  
500 Chipeta Way  
Salt Lake City, UT 84108

\* PERFORMING SITE

PATIENT NAME TESTING, 91937	ORDER STATUS Final	COLLECTION DATE AND TIME 05/21/09 11:48 A
--------------------------------	-----------------------	--

Specimen receipt and report times are in CST/CDT

REPRINT

Page 1 of 1